GlaxoSmithKline News and Research

RSS

Malaria Conference addresses RTS,S vaccine, tools, treatment

On Tuesday at the 5th Multilateral Initiative on Malaria (MIM) Pan-African Conference in Nairobi, Kenya, scientists and global health experts focused on malaria eradication, Agence France-Presse reports. "Key among the strategies ... is the development of an effective anti-malaria vaccine, a project scientists have been researching since the late 80s. ... RTS,S is the most clinically advanced malaria vaccine so far, according to the Malaria Vaccine Initiative," the news service writes (11/3).

3 Nov 2009

GlaxoSmithKline, Pfizer formally launch company to develop new HIV treatments

Pharmaceutical companies GlaxoSmithKline (GSK) and Pfizer on Tuesday formally launched ViiV Healthcare, a company focused on the development of new HIV treatments, Dow Jones Newswires/SmartMoney.com reports (11/3).

3 Nov 2009

Efficacy trial of the world's most clinically advanced malaria vaccine candidate underway

A pivotal efficacy trial of RTS,S, the world's most clinically advanced malaria vaccine candidate, is now underway in seven African countries: Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania. The trial, which is expected to involve up to 16,000 children, is on schedule, with more than 5,000 children already enrolled, researchers announced Tuesday at the 5th Multilateral Initiative on Malaria Pan-African Malaria Conference.

3 Nov 2009

Malaria conference begins in Nairobi, will highlight outlook for RTS,S experimental malaria vaccine

The 5th Multilateral Initiative on Malaria (MIM) Pan-African Conference "kicked off in Nairobi late Sunday with a call for substantial and sustained support for research to guide evidence-based policies and the development of new malaria tools, which together could save countless lives," Xinhua reports (11/2).

2 Nov 2009

Study of combination therapy versus monotherapy for pulmonary arterial hypertension

Gilead Sciences, Inc., in collaboration with GlaxoSmithKline (GSK), today announced plans for an international, event-driven (morbidity and mortality) clinical trial to study combination therapy versus monotherapy in a first-line treatment setting for pulmonary arterial hypertension (PAH).

2 Nov 2009

Valeant Pharmaceuticals announces financial results for the third quarter of 2009

Valeant Pharmaceuticals International today announced third quarter financial results for 2009.

2 Nov 2009

LRI and lupus organizations congratulate HGS and GlaxoSmithKline for achieving historical landmark

The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations congratulate Human Genome Sciences (HGS) and GlaxoSmithKline for achieving an historical landmark - the second positive phase 3 clinical trial of Benlysta (belimumab), the first successfully tested new drug developed specifically for people with systemic lupus.

2 Nov 2009

HGS and GSK announce results from phase III clinical trials of BENLYSTA

Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) today announced positive results from BLISS-76, the second of two large-scale phase III clinical trials of BENLYSTA(TM) (belimumab) for treating systemic lupus. A full presentation of results from BLISS-52 was recently shared at the 73rd Annual Scientific meeting of the American College of Rheumatology. Both trials succeeded in meeting their primary endpoints, which should make BENLYSTA eligible for approval by the U.S. Food and Drug Administration (FDA).

2 Nov 2009

BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). BLISS-76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with placebo plus standard of care.

2 Nov 2009

Highly publicized vaccine products not only boost pharmaceutical companies, but also benefit others

Highly publicized vaccine products not only boost the bottom lines of pharmaceutical companies, but also benefit insurance companies, doctors and retailers with their businesses, according to analysis of the recent flu vaccine season by life science market research publisher Kalorama Information.

30 Oct 2009

GSK will ensure experimental malaria vaccine is affordable, CEO says

GlaxoSmithKline CEO Andrew Witty said Wednesday the company would ensure that if an experimental malaria vaccine works, it would be priced reasonably, Reuters reports. "The vaccine, called Mosquirix [or RTS,S] and the first malaria shot to make it to final-stage trials, is creating a buzz ahead of a conference of 1,500 malaria experts in Nairobi next week," writes Reuters.

29 Oct 2009

Third-quarter fiscal 2009 results announced by Adolor

Adolor Corporation today reported a net loss of approximately $11.1 million, or ($0.24) per basic and diluted share, for the three months ended September 30, 2009 compared to a net loss of $13.3 million, or ($0.29) per basic and diluted share, for the three months ended September 30, 2008.

29 Oct 2009

Third-quarter 2009 financial results of Antigenics announced

Antigenics Inc. reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted.

29 Oct 2009

Winning placement on Managed Care formularies, the first step for product's increased market share

In today's payer-driven pharmaceutical marketplace, winning placement on Managed Care formularies marks only the first step for a product's increased market share. However 90 percent of executives working in Managed Care rate pull through tactics, such as health fairs and formulary update letters, as effective ways to impact demand after formulary placement.

29 Oct 2009

Report on marketing the bio-pharmaceutical products released

The bio-pharmaceutical marketplace - and the Oncology therapeutic area in particular - continues to evolve as new medicines and technologies create valuable market opportunities. It's in this competitive and challenging environment that organizations with new Oncology products are scrutinizing their strategies and tactics to support market education.

29 Oct 2009

Third-quarter fiscal 2009 results announced by POZEN

POZEN Inc., today announced results for the third quarter ended September 30, 2009.

28 Oct 2009

Experts release policy recommendations to promote better medication adherence and health outcomes

A diverse group of health care and consumer organizations released five policy recommendations this week that are designed to promote better medication adherence and improved health outcomes for patients.

28 Oct 2009

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.

27 Oct 2009

SuperGen and GSK team up to discover and develop cancer therapeutics based on epigenetic targets

SuperGen, Inc. (NASDAQ:SUPG) and GlaxoSmithKline (NYSE:GSK) have entered into a multi-year collaboration to discover and develop cancer therapeutics based on epigenetic targets.

26 Oct 2009

GlaxoSmithKline's CERVARIX recommended by CDC for protection against cervical cancer

GlaxoSmithKline announced today that the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) recommended that CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] be given to girls and young women to protect against cervical pre-cancers and cervical cancer caused by oncogenic HPV 16 and 18.

22 Oct 2009

GlaxoSmithKline News and Research

Malaria Conference addresses RTS,S vaccine, tools, treatment

GlaxoSmithKline, Pfizer formally launch company to develop new HIV treatments

Efficacy trial of the world's most clinically advanced malaria vaccine candidate underway

Malaria conference begins in Nairobi, will highlight outlook for RTS,S experimental malaria vaccine

Study of combination therapy versus monotherapy for pulmonary arterial hypertension

Valeant Pharmaceuticals announces financial results for the third quarter of 2009

LRI and lupus organizations congratulate HGS and GlaxoSmithKline for achieving historical landmark

HGS and GSK announce results from phase III clinical trials of BENLYSTA

BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus

Highly publicized vaccine products not only boost pharmaceutical companies, but also benefit others

GSK will ensure experimental malaria vaccine is affordable, CEO says

Third-quarter fiscal 2009 results announced by Adolor

Third-quarter 2009 financial results of Antigenics announced

Winning placement on Managed Care formularies, the first step for product's increased market share

Report on marketing the bio-pharmaceutical products released

Third-quarter fiscal 2009 results announced by POZEN

Experts release policy recommendations to promote better medication adherence and health outcomes

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

SuperGen and GSK team up to discover and develop cancer therapeutics based on epigenetic targets

GlaxoSmithKline's CERVARIX recommended by CDC for protection against cervical cancer

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News